Key Stats for AbbVie Stock
- Current Price: $264.34
- Target Price (Mid): ~$363
- Street Target: ~$279
- Potential Total Return: ~37%
- Annualized IRR: ~8% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
The FDA approved Juvmo (tavapadon), a once-daily Parkinson’s pill from AbbVie (ABBV), on Friday, September 25, according to Reuters. In a September 28 release, AbbVie said it expects to make Juvmo available to U.S. patients in October 2026. The company called it “the first and only selective D1/D5 receptor agonist” for adult Parkinson’s disease.
Ten days before the approval, management had already told investors the launch would start slowly. Shares closed September 25 at $264.34, up 15.69% in 2026 and 1.87% below TIKR’s 52-week high of $269.39. AbbVie’s investor relations materials show second-quarter neuroscience revenue rose 20.3% to $3.228 billion.
Management Says Juvmo Missed Medicare’s 2027 Window
At Morgan Stanley’s healthcare conference on September 15, Executive Vice President and Chief Commercial Officer Jeffrey Stewart said: “given our timing of the launch, we sort of missed the window for sort of Medicare reimbursement for ’27. So we’ll have a little bit of a slower burn.” An October launch gets Juvmo to patients, but Stewart’s point was about Medicare payment, not availability.
Stewart said AbbVie has guided its Parkinson’s franchise to a $5 billion peak. Its two Parkinson’s infusions brought in $863 million in 2025. Vyalev jumped to $482 million from $99 million, partly offset by Duodopa’s slide to $381 million from $447 million.
Stewart also said Vyalev will reach blockbuster status globally in 2026. That label usually means $1 billion or more in annual sales, roughly double its 2025 total. Juvmo was tested against placebo, not head-to-head against levodopa or older dopamine agonists, so uptake depends on doctors choosing once-daily dosing while coverage catches up.
See historical and forward estimates for AbbVie stock (It’s free!) >>>
The Payoff Sits in AbbVie’s 2030 Forecasts
TIKR’s estimate revisions show consensus 2030 revenue up about 3% since June 30, to around $86 billion. The 2026 figure rose only about 0.5% over the same period. Part of the move may reflect wider coverage, since analysts with 2030 estimates rose to 13 from 9, and consensus still sees growth slowing to under 3% in 2030.
On migraine, Chairman and CEO Robert Michael said: “we’ve said, again, $5 billion-plus peak and at least sell-side consensus has it around $4 billion, so another source of upside for us.” Head of R&D and Chief Scientific Officer Roopal Thakkar targeted a launch “in the early part of 2030” for zumilokibart. That atopic dermatitis drug came from the $10.9 billion Apogee deal.
In oncology, full Phase 3 CERVINO results for etentamig were presented at the International Myeloma Society meeting, held September 23 to 26. They showed a 74.0% response rate versus 45.7% for standard therapies in relapsed or refractory multiple myeloma, OncLive reported. AbbVie announced topline results on September 3, and Thakkar said the company aims to file in 2026.
AbbVie trades at around 17 times next-twelve-months normalized earnings, a P/E ratio up from around 15 times at the end of March. That is level with Amgen (AMGN), Biogen (BIIB) and Gilead Sciences (GILD) at around 17 to 18 times.
The Street’s mean target of around $279 sits about 5% above the price. Ratings stand at 16 Buy, 8 Outperform, 5 Hold, and 1 Underperform.
See how AbbVie performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $264.34
- Target Price (Mid): ~$363
- Potential Total Return: ~37%
- Annualized IRR: ~8% / year
See analysts’ growth forecasts and price targets for AbbVie stock (It’s free!) >>>
The mid-case is the only scenario the model shows at the December 31, 2030, horizon. It puts AbbVie at around $363, about 37% above $264.34, or around 8% a year.
The model’s mid-case assumptions, set across its 2025 to 2035 forecast, call for revenue growth of around 5% a year and a net income margin of around 42%. That compares with a 29.1% normalized margin in 2025. Upside comes if migraine and zumilokibart outrun expectations, as Michael argues for migraine. Downside comes if Juvmo’s slow ramp, plus the roughly $0.46 hit to 2027 adjusted EPS that AbbVie expects from Apogee, keeps margins short of 42%.
Conclusion
The next checkpoint is AbbVie’s third-quarter report, measured against adjusted EPS guidance of $3.84 to $3.88 that AbbVie reaffirmed on September 3. A result at the top of that range, with neuroscience growth near the second quarter’s 20.3%, would show the Parkinson’s franchise can carry the wait. The fourth quarter is the first that can include Juvmo sales, and early coverage commentary will show how slow Stewart’s “slower burn” really is.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in AbbVie?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AbbVie, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
